JP2017506630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506630A5 JP2017506630A5 JP2016550779A JP2016550779A JP2017506630A5 JP 2017506630 A5 JP2017506630 A5 JP 2017506630A5 JP 2016550779 A JP2016550779 A JP 2016550779A JP 2016550779 A JP2016550779 A JP 2016550779A JP 2017506630 A5 JP2017506630 A5 JP 2017506630A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- seq
- amino acid
- group
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000006850 spacer group Chemical group 0.000 claims 7
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000004503 Perforin Human genes 0.000 claims 3
- 108010056995 Perforin Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229940028652 abraxane Drugs 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- -1 bevacizumab Chemical compound 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229960004130 itraconazole Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1402006.9 | 2014-02-06 | ||
| GB201402006A GB201402006D0 (en) | 2014-02-06 | 2014-02-06 | Antibody-drug conjugates and immunotoxins |
| PCT/EP2015/052341 WO2015118030A2 (en) | 2014-02-06 | 2015-02-04 | Antibody-drug conjugates and immunotoxins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506630A JP2017506630A (ja) | 2017-03-09 |
| JP2017506630A5 true JP2017506630A5 (2) | 2018-03-15 |
| JP6619743B2 JP6619743B2 (ja) | 2019-12-11 |
Family
ID=50390517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550779A Active JP6619743B2 (ja) | 2014-02-06 | 2015-02-04 | 抗体−薬物複合体及び免疫毒素 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10137202B2 (2) |
| EP (1) | EP3102244B1 (2) |
| JP (1) | JP6619743B2 (2) |
| KR (1) | KR102342935B1 (2) |
| CN (1) | CN105979971B (2) |
| AU (1) | AU2015215015B2 (2) |
| CA (1) | CA2937455C (2) |
| DK (1) | DK3102244T3 (2) |
| ES (1) | ES2788864T3 (2) |
| GB (1) | GB201402006D0 (2) |
| HU (1) | HUE049291T2 (2) |
| MX (1) | MX375383B (2) |
| PL (1) | PL3102244T3 (2) |
| PT (1) | PT3102244T (2) |
| SI (1) | SI3102244T1 (2) |
| WO (1) | WO2015118030A2 (2) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| KR20180090290A (ko) | 2015-12-04 | 2018-08-10 | 시애틀 지네틱스, 인크. | 사차화 튜불리신 화합물들의 컨쥬게이트들 |
| AU2019271263A1 (en) * | 2018-05-16 | 2020-12-03 | Dragonfly Therapeutics, Inc. | Protein binding NKG2D, CD16 and a fibroblast activation protein |
| FI3997103T3 (fi) | 2019-07-08 | 2025-02-03 | 3B Pharmaceuticals Gmbh | Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| JP7801207B2 (ja) | 2019-07-08 | 2026-01-16 | ３ベー ファーマシューティカルズ ゲーエムベーハー | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
| CN111499685A (zh) * | 2020-03-30 | 2020-08-07 | 联宁（苏州）生物制药有限公司 | 具有马来酰亚胺连接头的抗体偶联药物中间体及其合成方法 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| IL300534A (en) | 2020-08-11 | 2023-04-01 | Kanaph Therapeutics Inc | A fusion protein containing 12-il and an anti-fap antibody, and its use |
| JP2023541601A (ja) | 2020-09-10 | 2023-10-03 | プレシリックス・ナームローゼ・ベンノートシヤープ | Ｆａｐに対する抗体フラグメント |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| IL303925A (en) | 2021-01-07 | 2023-08-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| KR20230121685A (ko) | 2022-02-11 | 2023-08-21 | 주식회사 카나프테라퓨틱스 | Il-12 및 항-fap 항체를 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| KR20230162310A (ko) | 2022-05-20 | 2023-11-28 | 주식회사 카나프테라퓨틱스 | Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도 |
| EP4311557A1 (en) | 2022-07-26 | 2024-01-31 | Oncomatryx Biopharma, S.L. | Fap-targeted antibody-drug conjugates |
| WO2025141153A1 (en) * | 2023-12-29 | 2025-07-03 | Oncomatryx Biopharma, S.L. | Endo180 targeted antibody-drug conjugates |
| EP4616869A1 (en) | 2024-03-15 | 2025-09-17 | Oncomatryx Biopharma, S.L. | Fap targeted antibody-drug conjugates |
| EP4684806A1 (en) | 2024-07-22 | 2026-01-28 | Oncomatryx Biopharma, S.L. | Fap-targeted antibody-drug conjugates |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4318752B2 (ja) | 1996-05-31 | 2009-08-26 | ヘルス・リサーチ・インコーポレーテッド | 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用 |
| EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US20020099180A1 (en) | 2000-03-17 | 2002-07-25 | Klaus Pfizenmaier | Human FAP-alpha-specific antibodies |
| EP1268550A2 (en) * | 2000-03-17 | 2003-01-02 | Boehringer Ingelheim Pharma KG | Human fap-alpha-specific antibodies |
| WO2005108419A1 (en) | 2004-05-07 | 2005-11-17 | Lea-Ann Kirkham | Mutant cholesterol-binding cytolysin proteins |
| JP4806680B2 (ja) * | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| DE102005036542A1 (de) * | 2005-08-03 | 2007-02-08 | Universität Stuttgart | CTL-Prodrug |
| EP1806365A1 (en) * | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| AU2008224988A1 (en) | 2007-03-14 | 2008-09-18 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
| WO2008138561A1 (en) | 2007-05-10 | 2008-11-20 | R & D Biopharmaceuticals Gmbh | Tubulysine derivatives |
| CN102339094A (zh) * | 2010-07-21 | 2012-02-01 | 英业达股份有限公司 | 服务器 |
| CA2806021C (en) * | 2010-08-13 | 2019-05-21 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| RU2014124984A (ru) * | 2011-12-05 | 2016-01-27 | Идженика Биотерапьютикс, Инк. | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
| CN104640572B (zh) * | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| ES2781523T3 (es) * | 2012-07-12 | 2020-09-02 | Hangzhou Dac Biotech Co Ltd | Conjugados de moléculas de unión celular con agentes citotóxicos |
| WO2015113760A1 (en) * | 2014-01-28 | 2015-08-06 | Tube Pharmaceuticals Gmbh | Cytotoxic tubulysin compounds for conjugation |
| GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
-
2014
- 2014-02-06 GB GB201402006A patent/GB201402006D0/en not_active Ceased
-
2015
- 2015-02-04 KR KR1020167021198A patent/KR102342935B1/ko active Active
- 2015-02-04 MX MX2016010127A patent/MX375383B/es active IP Right Grant
- 2015-02-04 CA CA2937455A patent/CA2937455C/en active Active
- 2015-02-04 US US15/116,430 patent/US10137202B2/en active Active
- 2015-02-04 ES ES15705778T patent/ES2788864T3/es active Active
- 2015-02-04 AU AU2015215015A patent/AU2015215015B2/en active Active
- 2015-02-04 SI SI201531229T patent/SI3102244T1/sl unknown
- 2015-02-04 PT PT157057787T patent/PT3102244T/pt unknown
- 2015-02-04 WO PCT/EP2015/052341 patent/WO2015118030A2/en not_active Ceased
- 2015-02-04 DK DK15705778.7T patent/DK3102244T3/da active
- 2015-02-04 HU HUE15705778A patent/HUE049291T2/hu unknown
- 2015-02-04 PL PL15705778T patent/PL3102244T3/pl unknown
- 2015-02-04 JP JP2016550779A patent/JP6619743B2/ja active Active
- 2015-02-04 CN CN201580006995.5A patent/CN105979971B/zh active Active
- 2015-02-04 EP EP15705778.7A patent/EP3102244B1/en active Active
-
2018
- 2018-10-16 US US16/162,211 patent/US10864278B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506630A5 (2) | ||
| JP2017506234A5 (2) | ||
| JP2017518040A5 (2) | ||
| IL317587A (en) | Antibody against SIRPalpha | |
| JP2020502271A5 (2) | ||
| JP2018505177A5 (2) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2017528476A5 (2) | ||
| JP2017530722A5 (2) | ||
| JP2013510868A5 (2) | ||
| JP2020503001A5 (2) | ||
| JP2010535713A5 (2) | ||
| JP2017500028A5 (2) | ||
| JP2018070648A5 (2) | ||
| JP2015509947A5 (2) | ||
| JP2016523810A5 (2) | ||
| JP2017519759A5 (2) | ||
| JP2017510661A5 (2) | ||
| JP2017534256A5 (2) | ||
| JP2018516243A5 (2) | ||
| JP2017514461A5 (2) | ||
| JP2016538318A5 (2) | ||
| JP2008500815A5 (2) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2018511628A5 (2) |